Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.40 |
| ▸ | NRP1 | O14786 | 2/20 | 0.37 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31416512 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2EPHX2C3AR1CPB2SHMT1 | |
| SCHEMBL29827128 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2EPHX2C3AR1CPB2SHMT1 | |
| Acetic Acid SCHEMBL31070917 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2EPHX2CPB2 | |
| SCHEMBL24804881 | 0.79 | C3AR1 (0.49) | C3AR1CPB2SHMT1CTDSP1NOD1 | |
| SCHEMBL30193317 | 0.78 | NOD1 (0.50) | C3AR1NRP1SHMT1CTDSP1NOD1 | |
| SCHEMBL30193454 | 0.78 | PRCP (0.44) | C3AR1CPB2NRP1 | |
| SCHEMBL2115693 | 0.77 | NOD1 (0.54) | C3AR1SHMT1CTDSP1NOD1 | |
| SCHEMBL3818717 | 0.77 | NOD1 (0.54) | C3AR1SHMT1CTDSP1NOD1 | |
| SCHEMBL25875020 | 0.76 | C3AR1 (0.47) | C3AR1CPB2SHMT1CTDSP1NOD1 | |
| SCHEMBL12222096 | 0.76 | C3AR1 (0.47) | C3AR1CPB2SHMT1CTDSP1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400616-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BICYCLETX LIMITED (GB) | 2024-12-05 | — | — | US | claimed |
| CN-117136066-A | Nectin-4 targeting peptide compounds and drug conjugates thereof | 上海智肽生物科技有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-119303102-A | Double-target cyclopeptide coupling medicine, medicine composition and application thereof | 博瑞生物医药（苏州）股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-117136066-A | Nectin-4 targeting peptide compounds and drug conjugates thereof | 上海智肽生物科技有限公司 | 2023-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400616-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | NECTIN4, VCAM1, SIGLEC7 | SMN1; SMN2 2834/4885EPHX2 3579/4885C3AR1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.